FULL LIFE TECHNOLOGIES
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Full-Life Technologies Announces the Appointment of Edward (Ted) Myles to Its Board of Directors 2024-07-22 08:00
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors 2024-07-17 10:00
Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting 2024-06-11 08:00
Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer 2024-05-30 08:00
Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer 2024-05-17 08:00
Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction 2024-03-26 08:00
Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals 2023-12-08 10:00
Full-Life Technologies Announces Land Purchase in Belgium to Establish GMP Manufacturing Facility for Radiopharmaceutical Drug Production 2023-05-04 10:00
Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer 2023-01-17 10:00
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline 2022-11-29 10:00
Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board 2022-08-10 12:00
Full-Life Technologies Completes $37 Million (USD) Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform 2022-05-26 12:00
1